Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

Inclusion Criteria: * Age 50-85 * Any sex * Any ethnicity * Interest in taking Rapamycin off-label * Willing to undergo tests * Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable * Adequate cognitive function to be able to give informed consent * Technologically competent to complete web forms and perform video calls with the PI Exclusion Criteria: * Anemia - Hg \< 9.0 g/dl, Leukopenia - white blood cells (WBC) \< 3,500/mm3 , Neutropenia - absolute neutrophil count \< 2,000/mm3 , or Platelet count - platelet count \< 125,000/mm3 * Premenopausal females (due to menstruation-induced anemia, etc.) * Patients scheduled to undergo major surgery in the next 12 months * Patients undergoing or scheduled to undergo chemotherapy or any other treatment for malignancy * Patients scheduled for immunosuppressant therapy for transplant * Patients with impaired wound healing or history of a chronic open wound * Untreated dyslipidemia with LDL-c \> 190 and family history of dyslipidemia, Total cholesterol \> 350 mg/dl, or triglycerides \> 880 mg/dl. * Impaired hepatic function, including elevated alkaline Phosphatase levels, aspartate aminotransferase (AST), alanine aminotransferase (ALT), Albumin, or T. Bili. * HIV/AIDS, chronic Lyme, Babesia, Ehrlichiosis, Anaplasmosis, or other chronic infections that require ongoing treatment or monitoring * Allergy to Rapamycin * Any form of clinically releva…